MiMedx Group (MDXG) Projected to Post Quarterly Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect MiMedx Group to post earnings of $0.09 per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

MiMedx Group Stock Up 0.8%

MiMedx Group stock opened at $5.16 on Wednesday. MiMedx Group has a 52-week low of $4.89 and a 52-week high of $8.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The firm has a 50 day moving average price of $6.01 and a two-hundred day moving average price of $6.68. The firm has a market cap of $764.20 million, a price-to-earnings ratio of 19.11 and a beta of 1.59.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on MDXG shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Cantor Fitzgerald reduced their price target on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday. Mizuho dropped their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. Finally, Lake Street Capital decreased their target price on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, MiMedx Group presently has a consensus rating of “Moderate Buy” and an average price target of $9.33.

Institutional Investors Weigh In On MiMedx Group

Large investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. bought a new position in MiMedx Group during the fourth quarter valued at about $48,000. Jain Global LLC bought a new position in shares of MiMedx Group during the 4th quarter valued at approximately $73,000. Headlands Technologies LLC purchased a new stake in shares of MiMedx Group during the 2nd quarter worth approximately $72,000. Cresset Asset Management LLC bought a new stake in shares of MiMedx Group in the 3rd quarter worth approximately $86,000. Finally, CIBC Bancorp USA Inc. purchased a new position in MiMedx Group in the third quarter valued at approximately $88,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.